José Roberto de Oliveira Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
José Roberto de Oliveira Ferreira has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Michel Pinheiro Ferreira
Federal University of Piaui
7 shared publications Bruno Coêlho Cavalcanti
Federal University of Ceará
3 shared publications- Bruno Coêlho Cavalcanti
Federal University of Ceará
3 shared publications - Felipe Cavalcanti Carneiro da Silva
Department of Biological Sciences, Federal University of Piauí, Picos, Brazil
3 shared publications - Claudia Pessoa
Universidade Federal do Ceará, Brasil
2 shared publications - Débora Caroline Do Nascimento Rodrigues
Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Federal University of Piauí
2 shared publications
Latest Publications
- 23 March 2026
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 89 (20) , 1-11
Assessment of the genotoxicity and pro-oxidative potentials of risperidone in L929 murine fibroblasts
Risperidone is an atypical antipsychotic drug clinically used to treat mood disorders, autism, and schizophrenia. Since risperidone is typically prescribed chronically for clinical use, it is important to determine potential side effects, such as toxicogenic consequences, which remain under-explored for this class of drugs. The main goal of this study was to (1) examine the genotoxicity attributed to risperidone using L929 murine fibroblasts with different standardized techniques (MTT, comet, and micronucleus (MN) assays) and (2) and oxidative potential by measuring levels of reduced glutathione (GSH) and carbonyl proteins, oxidative indices. Data demonstrated that risperidone exhibited a cytotoxic effect after 24 hr exposure, reducing cell viability by approximately 23% (compared to negative controls) at the highest concentration (500 µM). Standard alkaline comet (pH > 13) and MN assays noted the absence of genotoxic/mutagenic potentials after treatment with risperidone (100 and 500 µM), even in the presence of an exogenous metabolizing source (S9 fraction). However, the comet assay displayed the presence of the enzyme formamidopyrimidine DNA-glycosylase (FPG) in cells exposed to 500 µM risperidone resulting in a significant increase in levels of DNA damage, indicative of oxidative damage to the genome. This oxidative DNA damage was corroborated by reduction of the glutathione (GSH) levels, through modulation of GSH-dependent enzymes, and elevated levels of protein oxidation in cultures exposed to 500 µM risperidone. Data demonstrated that 500 µM risperidone exerted a cytotoxic effect on L929 cells accompanied by induction of DNA strand breaks generation of oxidative stress.
- 23 March 2026
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 89 (20) , 1-11
Assessment of the genotoxicity and pro-oxidative potentials of risperidone in L929 murine fibroblasts
Risperidone is an atypical antipsychotic drug clinically used to treat mood disorders, autism, and schizophrenia. Since risperidone is typically prescribed chronically for clinical use, it is important to determine potential side effects, such as toxicogenic consequences, which remain under-explored for this class of drugs. The main goal of this study was to (1) examine the genotoxicity attributed to risperidone using L929 murine fibroblasts with different standardized techniques (MTT, comet, and micronucleus (MN) assays) and (2) and oxidative potential by measuring levels of reduced glutathione (GSH) and carbonyl proteins, oxidative indices. Data demonstrated that risperidone exhibited a cytotoxic effect after 24 hr exposure, reducing cell viability by approximately 23% (compared to negative controls) at the highest concentration (500 µM). Standard alkaline comet (pH > 13) and MN assays noted the absence of genotoxic/mutagenic potentials after treatment with risperidone (100 and 500 µM), even in the presence of an exogenous metabolizing source (S9 fraction). However, the comet assay displayed the presence of the enzyme formamidopyrimidine DNA-glycosylase (FPG) in cells exposed to 500 µM risperidone resulting in a significant increase in levels of DNA damage, indicative of oxidative damage to the genome. This oxidative DNA damage was corroborated by reduction of the glutathione (GSH) levels, through modulation of GSH-dependent enzymes, and elevated levels of protein oxidation in cultures exposed to 500 µM risperidone. Data demonstrated that 500 µM risperidone exerted a cytotoxic effect on L929 cells accompanied by induction of DNA strand breaks generation of oxidative stress.
- Open Access
- 29 January 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 213, 108343
Antifungal and molecular analysis of gene expression caused by haloperidol in Candida spp.
- 29 January 2026
- Published by Elsevier in Microbial Pathogenesis
- Vol. 213, 108343
Open AccessAntifungal and molecular analysis of gene expression caused by haloperidol in Candida spp.
- Open Access
- 8 May 2025
- Published by Universidade Federal da Bahia in Revista de Ciências Médicas e Biológicas
- Vol. 24 (1) , 179-187
Conhecimento sobre a predisposição genética ao câncer de mama e ovário na capital de Alagoas, Nordeste do Brasil
Introdução: Os cânceres de mama e de ovário impactam muitas mulheres no Brasil. A Síndrome Hereditária do Câncer de Mama e Ovário (HBOC) representa 5 a 10% de todos os casos de tumores de mama e ovário diagnosticados e mutações nos genes BRCA1 e BRCA2 são as principais causas dos tumores nesses pacientes. Entretanto, o conhecimento sobre fatores de risco, prevenção e manejo apresenta divulgação deficitária. Objetivo: Caracterizar o conhecimento da população alagoana atendida no Sistema Único de Saúde acerca do impacto de fatores genéticos na predisposição hereditária a tumores de mama e ovário. Metodologia: Trata-se de um estudo observacional, do tipo transversal, de caráter quantitativo e qualitativo, por meio de questionário estruturado aplicado nos dois locais de atendimento público durante o período de agosto de 2023 a abril de 2024. A fim de relacionar as variáveis categóricas, foi realizado o teste qui-quadrado, com um nível de significância de 5%. Resultados: Analisando os 237 participantes, o público foi majoritariamente feminino 208 (89,3%), com escolaridade intermediária 105 (45,7%) e apresentou entendimento razoável dos riscos não genéticos. Notou-se que aqueles com maior escolaridade acertaram mais questões sobre o câncer de mama masculino (p=0,025) e hereditariedade familiar da neoplasia de mama (p=0,006). Por outro lado, um alto número afirma não conhecer a HBOC - 173 (93,5%). Conclusão: A combinação de estratégias de conscientização atuais com a abordagem ao fator de risco genético mostra-se crucial para melhorar as políticas de prevenção da doença.
- 8 May 2025
- Published by Universidade Federal da Bahia in Revista de Ciências Médicas e Biológicas
- Vol. 24 (1) , 179-187
Open AccessConhecimento sobre a predisposição genética ao câncer de mama e ovário na capital de Alagoas, Nordeste do Brasil
Introdução: Os cânceres de mama e de ovário impactam muitas mulheres no Brasil. A Síndrome Hereditária do Câncer de Mama e Ovário (HBOC) representa 5 a 10% de todos os casos de tumores de mama e ovário diagnosticados e mutações nos genes BRCA1 e BRCA2 são as principais causas dos tumores nesses pacientes. Entretanto, o conhecimento sobre fatores de risco, prevenção e manejo apresenta divulgação deficitária. Objetivo: Caracterizar o conhecimento da população alagoana atendida no Sistema Único de Saúde acerca do impacto de fatores genéticos na predisposição hereditária a tumores de mama e ovário. Metodologia: Trata-se de um estudo observacional, do tipo transversal, de caráter quantitativo e qualitativo, por meio de questionário estruturado aplicado nos dois locais de atendimento público durante o período de agosto de 2023 a abril de 2024. A fim de relacionar as variáveis categóricas, foi realizado o teste qui-quadrado, com um nível de significância de 5%. Resultados: Analisando os 237 participantes, o público foi majoritariamente feminino 208 (89,3%), com escolaridade intermediária 105 (45,7%) e apresentou entendimento razoável dos riscos não genéticos. Notou-se que aqueles com maior escolaridade acertaram mais questões sobre o câncer de mama masculino (p=0,025) e hereditariedade familiar da neoplasia de mama (p=0,006). Por outro lado, um alto número afirma não conhecer a HBOC - 173 (93,5%). Conclusão: A combinação de estratégias de conscientização atuais com a abordagem ao fator de risco genético mostra-se crucial para melhorar as políticas de prevenção da doença.
- 8 May 2025
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 48 (6) , 1500-1510
Arylacetamides exhibit antiproliferative effects on non-transformed mammalian and vegetal cells and toxicity on crustaceans and fish embryos
Non-clinical steps for development, validation and biosafety of new medicines and products comprises studies on cells, proteins, and animals. Herein, we evaluated the toxic activity of antitumoral 2-chloro-N-arylacetamides on eukaryotic dividing cells and animal replacement models. Firstly, the cytotoxicity of chloro (compound 2), bromo (compound 3) and nitro (compound 4) acetamides was analyzed by fluorescent assays in fibroblasts. Next, toxicity was evaluated on Allium cepa meristematic cells and 48h-living Artemia salina larvae. Finally, embryos of Danio rerio (zebrafish) were exposed to the compound 2 (0.14 - 7.2 μg/mL) for 120 h exposure. All arylacetamides were cytotoxic on murine and human fibroblasts, with IC50 values ranging from 1.2 μg/mL (5.6 µM = compound 4 on L-929) to 4.9 μg/mL (24 µM = compound 2 on MRC-5 cells), respectively, and inhibited root growth from 10 to 100 µg/mL, corroborated by mitotic index reduction and cell cycle arrest in interphase (p < 0.05) without clastogenic injuries. Compound 2 showed time- and concentration-dependent killing effects on zebrafish embryos. Its 24 h-acute toxicity at higher concentrations (1.93 and 7.2 μg/mL with 90% and 100% death) corroborated toxicity on aquatic A. salina organisms. After 96 h exposure at 0.52 μg/mL (2.55 µM), almost 100% of the embryos showed more than one lethal/sublethal morphological abnormality (p < 0.05). Then, all arylacetamides showed unspecific toxic effects, mainly the halogenated electrophile chloroacetamide. They present strong antimitotic action on vertebrate and vegetal cells, although such antiproliferative activity does not seem to be directly related to chromosomal damage inductions.
- 8 May 2025
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 48 (6) , 1500-1510
Arylacetamides exhibit antiproliferative effects on non-transformed mammalian and vegetal cells and toxicity on crustaceans and fish embryos
Non-clinical steps for development, validation and biosafety of new medicines and products comprises studies on cells, proteins, and animals. Herein, we evaluated the toxic activity of antitumoral 2-chloro-N-arylacetamides on eukaryotic dividing cells and animal replacement models. Firstly, the cytotoxicity of chloro (compound 2), bromo (compound 3) and nitro (compound 4) acetamides was analyzed by fluorescent assays in fibroblasts. Next, toxicity was evaluated on Allium cepa meristematic cells and 48h-living Artemia salina larvae. Finally, embryos of Danio rerio (zebrafish) were exposed to the compound 2 (0.14 - 7.2 μg/mL) for 120 h exposure. All arylacetamides were cytotoxic on murine and human fibroblasts, with IC50 values ranging from 1.2 μg/mL (5.6 µM = compound 4 on L-929) to 4.9 μg/mL (24 µM = compound 2 on MRC-5 cells), respectively, and inhibited root growth from 10 to 100 µg/mL, corroborated by mitotic index reduction and cell cycle arrest in interphase (p < 0.05) without clastogenic injuries. Compound 2 showed time- and concentration-dependent killing effects on zebrafish embryos. Its 24 h-acute toxicity at higher concentrations (1.93 and 7.2 μg/mL with 90% and 100% death) corroborated toxicity on aquatic A. salina organisms. After 96 h exposure at 0.52 μg/mL (2.55 µM), almost 100% of the embryos showed more than one lethal/sublethal morphological abnormality (p < 0.05). Then, all arylacetamides showed unspecific toxic effects, mainly the halogenated electrophile chloroacetamide. They present strong antimitotic action on vertebrate and vegetal cells, although such antiproliferative activity does not seem to be directly related to chromosomal damage inductions.
- Open Access
- 16 February 2024
- Published by Universidade Paranaense in Arquivos de Ciências da Saúde da UNIPAR
- Vol. 28 (1) , 174-187
PRÓPOLIS VERMELHA E AÇÃO ANTIFÚNGICA: POTENCIALIDADES E DESAFIOS
Introdução: a própolis é uma composição resinosa produzida por abelhas e utilizada em suas colmeias contra microrganismos. Existem diversos tipos desse composto, sendo o de coloração vermelha o último espécime relatado na literatura. Assim, dentre suas aplicabilidades, a atividade antifúngica da própolis vermelha tem sido explorada com vistas a ampliar sua ação terapêutica. Objetivo: explorar estudos acerca da ação antifúngica da própolis vermelha, identificando suas potencialidades e desafios. Metodologia: foi realizada uma revisão integrativa nas bases de dados bibliográficos MEDLINE (via PubMed), SciELO e Google Acadêmico, complementada por uma diligência nas bases de ensaios clínicos ReBEC e Clinical Trials. Em seguida todos os estudos selecionados foram explorados para obtenção do cenário atual sobre o tema. Resultados: foram incluídos 08 estudos, sendo 01 deles um ensaio clínico. Os estudos comprovam a ação antifúngica da própolis vermelha, principalmente contra Candida spp. e Paracoccidioides brasiliensis, e evidenciam a maior potência fungicida deste composto em detrimento de outros tipos de própolis. Conclusão: a ação antifúngica da própolis vermelha mostra-se uma potencialidade em diversos estudos. Entretanto, o volume de pesquisas científicas relativas a esse tema é insuficiente e a complexidade desse composto configura-se como um desafio à sua aplicabilidade.
- 16 February 2024
- Published by Universidade Paranaense in Arquivos de Ciências da Saúde da UNIPAR
- Vol. 28 (1) , 174-187
Open AccessPRÓPOLIS VERMELHA E AÇÃO ANTIFÚNGICA: POTENCIALIDADES E DESAFIOS
Introdução: a própolis é uma composição resinosa produzida por abelhas e utilizada em suas colmeias contra microrganismos. Existem diversos tipos desse composto, sendo o de coloração vermelha o último espécime relatado na literatura. Assim, dentre suas aplicabilidades, a atividade antifúngica da própolis vermelha tem sido explorada com vistas a ampliar sua ação terapêutica. Objetivo: explorar estudos acerca da ação antifúngica da própolis vermelha, identificando suas potencialidades e desafios. Metodologia: foi realizada uma revisão integrativa nas bases de dados bibliográficos MEDLINE (via PubMed), SciELO e Google Acadêmico, complementada por uma diligência nas bases de ensaios clínicos ReBEC e Clinical Trials. Em seguida todos os estudos selecionados foram explorados para obtenção do cenário atual sobre o tema. Resultados: foram incluídos 08 estudos, sendo 01 deles um ensaio clínico. Os estudos comprovam a ação antifúngica da própolis vermelha, principalmente contra Candida spp. e Paracoccidioides brasiliensis, e evidenciam a maior potência fungicida deste composto em detrimento de outros tipos de própolis. Conclusão: a ação antifúngica da própolis vermelha mostra-se uma potencialidade em diversos estudos. Entretanto, o volume de pesquisas científicas relativas a esse tema é insuficiente e a complexidade desse composto configura-se como um desafio à sua aplicabilidade.
- 13 June 2022
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 85 (18) , 750-766
Antimitotic and toxicogenetic action of Stevia urticifolia aerial parts on proliferating vegetal and mammalian cells: in vitro and in vivo traditional and replacement methods
Stevia urticifolia Thunb. is an underexploited herb possessing bioactive flavonoids, saponins, and terpenoids. The aim of this study was to examine the antiproliferative and toxicogenetic properties of the ethyl acetate extract from Stevia urticifolia aerial parts (EtAcSur) upon Artemia salina, erythrocytes, Allium cepa and sarcoma 180 cells and fibroblasts, as well as in vivo studies on mice to determine systemic, macroscopic, and behavioral alterations and bone marrow chromosomal damage. The assessment using A. salina larvae and mouse blood cells revealed LC50 and EC50 values of 68.9 and 113.6 µg/ml, respectively. Root growth and mitosis were inhibited by EtAcSur, and chromosomal aberrations were detected only at 100 μg/ml. EtAcSur exhibited potent concentration-dependent viability reduction of S180 and L-929 cells and antioxidant capacity employing ABTS• and DPPH•. No previous in vivo studies were performed before with the EtAcSur. Signals of acute toxicity were not observed at 300 mg/kg. Physiological and toxicological investigations at 25 and 50 mg/mg/day i.p. for 8 days did not markedly change body or organ relative weights, nor patterns of spontaneous locomotor and exploratory activities. In contrast, clastogenic effects on bone marrow were found at 50 mg/mg/day. EtAcSur was found to (1) produce toxicity in microcrustaceans, (2) capacity as free radical scavenger, (3) antimitotic, cytotoxic and clastogenic activties upon vegetal and mammalian cells, and (4) lethality on both tumor and normal murine cells indistinctly. In vivo damage systemic effects were not remarkable and clinical signals of toxicity were not observed, suggesting the significant pharmacological potential of S. urticifolia for the development of antineoplastic agents. Abbreviations: ABTS: 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid); DMSO: dimethylsulfoxide; DPPH: 1,1-diphenyl-2-picrylhydrazyl; EC50: effective concentration 50%; EtAcSur: ethyl acetate extract from Stevia urticifolia aerial parts; Hb, hemoglobin; IC50: inhibitory concentration 50%; LC50,: lethal concentration 50%; MI: mitotic index; RBC, red blood cells; Trolox: 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.
- 13 June 2022
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 85 (18) , 750-766
Antimitotic and toxicogenetic action of Stevia urticifolia aerial parts on proliferating vegetal and mammalian cells: in vitro and in vivo traditional and replacement methods
Stevia urticifolia Thunb. is an underexploited herb possessing bioactive flavonoids, saponins, and terpenoids. The aim of this study was to examine the antiproliferative and toxicogenetic properties of the ethyl acetate extract from Stevia urticifolia aerial parts (EtAcSur) upon Artemia salina, erythrocytes, Allium cepa and sarcoma 180 cells and fibroblasts, as well as in vivo studies on mice to determine systemic, macroscopic, and behavioral alterations and bone marrow chromosomal damage. The assessment using A. salina larvae and mouse blood cells revealed LC50 and EC50 values of 68.9 and 113.6 µg/ml, respectively. Root growth and mitosis were inhibited by EtAcSur, and chromosomal aberrations were detected only at 100 μg/ml. EtAcSur exhibited potent concentration-dependent viability reduction of S180 and L-929 cells and antioxidant capacity employing ABTS• and DPPH•. No previous in vivo studies were performed before with the EtAcSur. Signals of acute toxicity were not observed at 300 mg/kg. Physiological and toxicological investigations at 25 and 50 mg/mg/day i.p. for 8 days did not markedly change body or organ relative weights, nor patterns of spontaneous locomotor and exploratory activities. In contrast, clastogenic effects on bone marrow were found at 50 mg/mg/day. EtAcSur was found to (1) produce toxicity in microcrustaceans, (2) capacity as free radical scavenger, (3) antimitotic, cytotoxic and clastogenic activties upon vegetal and mammalian cells, and (4) lethality on both tumor and normal murine cells indistinctly. In vivo damage systemic effects were not remarkable and clinical signals of toxicity were not observed, suggesting the significant pharmacological potential of S. urticifolia for the development of antineoplastic agents. Abbreviations: ABTS: 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid); DMSO: dimethylsulfoxide; DPPH: 1,1-diphenyl-2-picrylhydrazyl; EC50: effective concentration 50%; EtAcSur: ethyl acetate extract from Stevia urticifolia aerial parts; Hb, hemoglobin; IC50: inhibitory concentration 50%; LC50,: lethal concentration 50%; MI: mitotic index; RBC, red blood cells; Trolox: 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.
- Open Access
- 16 January 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (2)
Produtos alimentícios à base de extrato de Cannabis: do “Brisadeiro” à busca por efeito terapêutico
Introdução. Os produtos comestíveis à base de maconha tornaram-se um mercado lucrativo e de grande procura. Apesar de no Brasil não ser legalizada, a maconha é encontrada em preparações orais comercializadas ilegalmente no país e a busca por esses produtos tem crescido nos últimos anos. O presente estudo tem por finalidade reunir dados da literatura científica sobre a fisiologia do sistema endocanabinóide, efeitos do consumo de Cânabis por via oral, farmacocinética, possíveis efeitos tóxicos, terapêuticos e formas de detecção, buscando contribuir para o preenchimento da lacuna ainda existente sobre o tema. Metodologia. Foi realizada revisão integrativa na base de dados PubMed para publicações dos últimos 5 anos em português, inglês e espanhol. Resultados. A pesquisa resultou em 128 artigos os quais foram removidos os trabalhos que não preenchessem os critérios de inclusão, restando 28 artigos utilizados. Conclusões. É necessário que seja realizado um número maior de ensaios clínicos com canabis por via oral, nas diversas formulações existentes, para melhor compreender sua farmacocinética, farmacodinâmica, potencialidades terapêuticas e seus efeitos adversos.
- 16 January 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (2)
Open AccessProdutos alimentícios à base de extrato de Cannabis: do “Brisadeiro” à busca por efeito terapêutico
Introdução. Os produtos comestíveis à base de maconha tornaram-se um mercado lucrativo e de grande procura. Apesar de no Brasil não ser legalizada, a maconha é encontrada em preparações orais comercializadas ilegalmente no país e a busca por esses produtos tem crescido nos últimos anos. O presente estudo tem por finalidade reunir dados da literatura científica sobre a fisiologia do sistema endocanabinóide, efeitos do consumo de Cânabis por via oral, farmacocinética, possíveis efeitos tóxicos, terapêuticos e formas de detecção, buscando contribuir para o preenchimento da lacuna ainda existente sobre o tema. Metodologia. Foi realizada revisão integrativa na base de dados PubMed para publicações dos últimos 5 anos em português, inglês e espanhol. Resultados. A pesquisa resultou em 128 artigos os quais foram removidos os trabalhos que não preenchessem os critérios de inclusão, restando 28 artigos utilizados. Conclusões. É necessário que seja realizado um número maior de ensaios clínicos com canabis por via oral, nas diversas formulações existentes, para melhor compreender sua farmacocinética, farmacodinâmica, potencialidades terapêuticas e seus efeitos adversos.
- Open Access
- 3 September 2021
- Published by Wiley in Journal of Oncology
- Vol. 2021, 1-18
Aminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features
The indiscriminate consumption of antimalarials against coronavirus disease-2019 emphasizes the longstanding clinical weapons of medicines. In this work, we conducted a review on the antitumor mechanisms of aminoquinolines, focusing on the responses and differences of tumor histological tissues and toxicity related to pharmacokinetics. This well-defined analysis shows similar mechanistic forms triggered by aminoquinolines in different histological tumor tissues and under coexposure conditions, although different pharmacological potencies also occur. These molecules are lysosomotropic amines that increase the antiproliferative action of chemotherapeutic agents, mainly by cell cycle arrest, histone acetylation, physiological changes in tyrosine kinase metabolism, inhibition of PI3K/Akt/mTOR pathways, cyclin D1, E2F1, angiogenesis, ribosome biogenesis, triggering of ATM-ATR/p53/p21 signaling, apoptosis, and presentation of tumor peptides. Their chemo/radiotherapy sensitization effects may be an adjuvant option against solid tumors, since 4-aminoquinolines induce lysosomal-mediated programmed cytotoxicity of cancer cells and accumulation of key markers, predominantly, LAMP1, p62/SQSTM1, LC3 members, GAPDH, beclin-1/Atg6, α-synuclein, and granules of lipofuscin. Adverse effects are dose-dependent, though most common with chloroquine, hydroxychloroquine, amodiaquine, and other aminoquinolines are gastrointestinal changes, blurred vision ventricular arrhythmias, cardiac arrest, QTc prolongation, severe hypoglycemia with loss of consciousness, and retinopathy, and they are more common with chloroquine than with hydroxychloroquine and amodiaquine due to pharmacokinetic features. Additionally, psychological/neurological effects were also detected during acute or chronic use, but aminoquinolines do not cross the placenta easily and low quantity is found in breast milk despite their long mean residence times, which depends on the coexistence of hepatic diseases (cancer-related or not), first pass metabolism, and comedications. The low cost and availability on the world market have converted aminoquinolines into star drugs for pharmaceutical repurposing, but a continuous pharmacovigilance is necessary because these antimalarials have multiple modes of action/unwanted targets, relatively narrow therapeutic windows, recurrent adverse effects, and related poisoning self-treatment. Therefore, their use must obey strict rules, ethical and medical prescriptions, and clinical and laboratory monitoring.
- 3 September 2021
- Published by Wiley in Journal of Oncology
- Vol. 2021, 1-18
Open AccessAminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features
The indiscriminate consumption of antimalarials against coronavirus disease-2019 emphasizes the longstanding clinical weapons of medicines. In this work, we conducted a review on the antitumor mechanisms of aminoquinolines, focusing on the responses and differences of tumor histological tissues and toxicity related to pharmacokinetics. This well-defined analysis shows similar mechanistic forms triggered by aminoquinolines in different histological tumor tissues and under coexposure conditions, although different pharmacological potencies also occur. These molecules are lysosomotropic amines that increase the antiproliferative action of chemotherapeutic agents, mainly by cell cycle arrest, histone acetylation, physiological changes in tyrosine kinase metabolism, inhibition of PI3K/Akt/mTOR pathways, cyclin D1, E2F1, angiogenesis, ribosome biogenesis, triggering of ATM-ATR/p53/p21 signaling, apoptosis, and presentation of tumor peptides. Their chemo/radiotherapy sensitization effects may be an adjuvant option against solid tumors, since 4-aminoquinolines induce lysosomal-mediated programmed cytotoxicity of cancer cells and accumulation of key markers, predominantly, LAMP1, p62/SQSTM1, LC3 members, GAPDH, beclin-1/Atg6, α-synuclein, and granules of lipofuscin. Adverse effects are dose-dependent, though most common with chloroquine, hydroxychloroquine, amodiaquine, and other aminoquinolines are gastrointestinal changes, blurred vision ventricular arrhythmias, cardiac arrest, QTc prolongation, severe hypoglycemia with loss of consciousness, and retinopathy, and they are more common with chloroquine than with hydroxychloroquine and amodiaquine due to pharmacokinetic features. Additionally, psychological/neurological effects were also detected during acute or chronic use, but aminoquinolines do not cross the placenta easily and low quantity is found in breast milk despite their long mean residence times, which depends on the coexistence of hepatic diseases (cancer-related or not), first pass metabolism, and comedications. The low cost and availability on the world market have converted aminoquinolines into star drugs for pharmaceutical repurposing, but a continuous pharmacovigilance is necessary because these antimalarials have multiple modes of action/unwanted targets, relatively narrow therapeutic windows, recurrent adverse effects, and related poisoning self-treatment. Therefore, their use must obey strict rules, ethical and medical prescriptions, and clinical and laboratory monitoring.
- Open Access
- 5 October 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0139753
Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome
Lynch syndrome (LS) accounts for 3–5% of all colorectal cancers (CRC) and is inherited in an autosomal dominant fashion. This syndrome is characterized by early CRC onset, high incidence of tumors in the ascending colon, excess of synchronous/metachronous tumors and extra-colonic tumors. Nowadays, LS is regarded of patients who carry deleterious germline mutations in one of the five mismatch repair genes (MMR), mostly in MLH1 and MSH2, but also in MSH6, PMS1 and PMS2. To comprehensively characterize 116 Brazilian patients suspected for LS, we assessed the frequency of germline mutations in the three minor genes MSH6, PMS1 and PMS2 in 82 patients negative for point mutations in MLH1 and MSH2. We also assessed large genomic rearrangements by MLPA for detecting copy number variations (CNVs) in MLH1, MSH2 and MSH6 generating a broad characterization of MMR genes. The complete analysis of the five MMR genes revealed 45 carriers of pathogenic mutations, including 25 in MSH2, 15 in MLH1, four in MSH6 and one in PMS2. Eleven novel pathogenic mutations (6 in MSH2, 4 in MSH6 and one in PMS2), and 11 variants of unknown significance (VUS) were found. Mutations in the MLH1 and MSH2 genes represented 89% of all mutations (40/45), whereas the three MMR genes (MSH6, PMS1 and PMS2) accounted for 11% (5/45). We also investigated the MLH1 p.Leu676Pro VUS located in the PMS2 interaction domain and our results revealed that this variant displayed no defective function in terms of cellular location and heterodimer interaction. Additionally, we assessed the tumor phenotype of a subset of patients and also the frequency of CRC and extra-colonic tumors in 2,365 individuals of the 116 families, generating the first comprehensive portrait of the genetic and clinical aspects of patients suspected of LS in a Brazilian cohort.
- 5 October 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0139753
Open AccessClinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome
Lynch syndrome (LS) accounts for 3–5% of all colorectal cancers (CRC) and is inherited in an autosomal dominant fashion. This syndrome is characterized by early CRC onset, high incidence of tumors in the ascending colon, excess of synchronous/metachronous tumors and extra-colonic tumors. Nowadays, LS is regarded of patients who carry deleterious germline mutations in one of the five mismatch repair genes (MMR), mostly in MLH1 and MSH2, but also in MSH6, PMS1 and PMS2. To comprehensively characterize 116 Brazilian patients suspected for LS, we assessed the frequency of germline mutations in the three minor genes MSH6, PMS1 and PMS2 in 82 patients negative for point mutations in MLH1 and MSH2. We also assessed large genomic rearrangements by MLPA for detecting copy number variations (CNVs) in MLH1, MSH2 and MSH6 generating a broad characterization of MMR genes. The complete analysis of the five MMR genes revealed 45 carriers of pathogenic mutations, including 25 in MSH2, 15 in MLH1, four in MSH6 and one in PMS2. Eleven novel pathogenic mutations (6 in MSH2, 4 in MSH6 and one in PMS2), and 11 variants of unknown significance (VUS) were found. Mutations in the MLH1 and MSH2 genes represented 89% of all mutations (40/45), whereas the three MMR genes (MSH6, PMS1 and PMS2) accounted for 11% (5/45). We also investigated the MLH1 p.Leu676Pro VUS located in the PMS2 interaction domain and our results revealed that this variant displayed no defective function in terms of cellular location and heterodimer interaction. Additionally, we assessed the tumor phenotype of a subset of patients and also the frequency of CRC and extra-colonic tumors in 2,365 individuals of the 116 families, generating the first comprehensive portrait of the genetic and clinical aspects of patients suspected of LS in a Brazilian cohort.